Do you have a large network and want to help companies in Västerbotten to find the right competence? Then you are welcome to join our advisory board.
Two representatives of the UBI company Mucocort have published an article in the Stockholm Intellectual Property Law Review on one of the most interesting research discoveries the recent decades – the discovery of CRISPR/Cas9, which can result in a Nobel Prize.
A new report has busted many of the myths surrounding super entrepreneurs, claiming they do not generally have higher IQs than the average person and are not necessarily driven by revenge following a troubled childhood.
The report, compiled by the Stockholm-based Sting incubator together with Umeå Biotech Incubator and researchers from Karolinska Institutet also discovered several important abilities that characterise successful entrepreneurs.
Swedish life science company Omnio has received millions in funding from the Swelife innovation programme to help develop a cure for tooth loss.
“Thanks to these funds from Swelife we can now move forward even faster”, says Omnio’s CEO Patric Stafshede.
Former Olympic biathlete Anders Mannelqvist has been appointed the new CEO of Pro Test Diagnostics, a Life Science company that has developed a unique test kit for blood doping.
Life science industry figurehead Pernilla Abrahamsson has left her position as Product Development Manager at stock market listed Senzime to become Chief Operating Officer (COO) at Lipum, located at the Umeå Biotech Incubator.
Umeå-based life science company Inficure Bio has just won the largest contract in its history.
“It feels incredible! The more large customers we get the greater our credibility becomes. This agreement is a real feather in our cap”, says Sofia Mayans, CEO of Inficure Bio.
Umeå life science company Lipum will participate in one of the world’s largest congresses for rheumatic diseases this June.
“The elite of our industry gathers at this congress once a year and competition is incredibly intense. It’s important to be seen there”, says Einar Pontén, CEO of Lipum.
Life science company Inficure Bio has been awarded millions by Vinnova to support the company’s development of a model that will help create new treatments for fibrosis.
“This money is incredibly important to us. Thanks to this investment we can now finish developing a new product”, says Sofia Mayans, CEO of Inficure Bio.
Small and medium-sized life science companies operating in the Västerbotten county in Sweden will double in numbers over the next ten years, while a vibrant scientific community will add to the growth. These are the goals set by Umeå Biotech Incubator (UBI), which is now entering a new development phase of its incubator operation in Umeå.
BioEurope Spring in Vienna with 2 486 delegates, ranging from International investors to major companies. Our business coach Helén is in Vienna representing UBI and life science in northern Sweden.
For the eleventh year in a row Umeå Biotech Incubator hosted the Biotech Umeå Investment Day (BUID) (last Thursday) at Stockholm’s Grand Hôtel, when investors from Sweden and abroad got the opportunity to meet 12 companies from Västerbotten.
UBI:s kommunikationsansvariga, Carolina Hawranek, kommer under våren lämna sin postition för att istället att forska på heltid. Vi frågar lite om hennes tid på här UBI och om flytten till Umeå.
Researchers from Quretech Bio AB (Quretech Bio) in Umeå, who were awarded a research grant of approximately SEK 25 million in the summer, have been awarded additional funding of just over SEK 17 million this autumn (made up of SEK 7.5 million from the Swedish Research Council, SEK 8 million from the Erling Persson Family Foundation and SEK 2.1 million from Umeå University).
Recently, Uman Diagnostics received national attention after making it onto the list of “Sweden’s Super Companies 2018”. Niklas Norgren explains how an idea in the lab at Umeå University grew into a company and a success story.
Hiloprobe AB has signed off on a partnership deal with a group of public and private stakeholders who have come together to back this high-potential startup. Hiloprobe is now complemented with much needed business expertise – as Mattias Pettersson from Northern Light Capital joins the board of directors, The company aims to launch their product for improved colorectal cancer diagnosis by 2020.
Inficure Bio has developed a new mouse model, the N-IF model. Mice are used as model organisms for studying human biology due to the genetic and physiological conformity between mice and humans. N-IF mice are unique as they spontaneously develop pathological fibrosis, rather than it being induced. This pathological progress is therefore more natural and provides better and faster results.